AMRI continues to up capacity amid ‘evolution of pharma pipelines’

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/lovelyday12)
(Image: iStock/lovelyday12)
AMRI has more than doubled its bulk Active Pharmaceutical Ingredient (API) aseptic manufacturing capacity in response to an increasing need for sterile API and an evolving pharma pipeline, says CCO.

AMRI recently added a new multipurpose aseptic API line at its facility in Valladolid, Spain.

This new line – supported by a range of technologies – ensures aseptic processing of APIs with tailor-made specifications and control of the physical properties of the final product, including particle size distribution​,” George Svokos, chief commercial officer at AMRI told us.

The contract research, development, and manufacturing organization (CDMO) also recently announced the addition of an aseptic pre-filled syringe line at the company’s manufacturing facility in Albuquerque, NM, which Sovokos said adds the capacity to manufacture roughly 50m syringes per year.

There is growing interest by customers toward biologics, controlled substances, and other complex compounds, and our intent is to remain a key player for complex and sterile API development and manufacturing, as well as sterile dosage form development and manufacturing​,” he added.

As Svokos explained, there is "an evolution of pharma pipelines​" and an increasing need for sterile API.

"According to industry analysis, there are many parenteral products (existing and being approved) in the form of sterile suspensions and other such presentations – including certain inhaled or ophthalmic products – that require the use of sterile API in their manufacturing,​" he said, citing a Pharmaprojects Pharma R&D Annual Review. "This feeds well into our Drug Product business, which has capabilities in these types of sterile suspensions​." 

Over the past year, the Albany, NY-headquartered CDMO – which was acquired by a private equity firm in September​ – has invested more than $10m in its Spain facilities

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers